Vitamin B12: The Brain & Blood Booster? 🩸🧠💪
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Vitamin B12: Essential for Health 🩸🧠 Vitamin B12 is crucial for red blood cell formation, brain function, and DNA synthesis. Found in animal-based foods 🥛🍳🐟, those on vegan diets need fortified foods or supplements 💊. Deficiency can cause anemia, neurological issues, and cognitive decline ⚠️. High-risk groups include vegans, vegetarians, older adults, and individuals with malabsorption conditions 🏥. Maternal deficiency affects fetal development 🤰👶. Absorption declines with age, and severe cases (e.g., pernicious anemia) may require high-dose supplements or...
info_outline
☀️ Vitamin D: The Sunshine Nutrient for Strong Bones & Immunity? 🦴🛡️”
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Vitamin D is essential for bone health 🦴, immune function 🛡️, and muscle strength 🏋️. Deficiency is common and affects women 👩⚕️, young adults 🧑🎓, and non-Hispanic Black Americans. Main sources include sunlight ☀️, oily fish 🐟, eggs 🥚, and fortified foods 🥛. Recommended intake is 600-800 IU/day 💊. Studies show mixed results 📊, but it may help with cancer prevention 🎗️, autoimmune diseases 🧬, and cognitive function 🧠. Excessive intake ⚠️ can cause kidney stones 🩺 and hypercalcemia.
info_outline
🔥 Vitamin D & Multiple Sclerosis: Defending the Nervous System 🧠🛡️
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🧠 High-dose Vitamin D (100,000 IU biweekly) reduced disease activity in Clinically Isolated Syndrome (CIS) of MS 🌞📉. Patients had fewer MRI lesions 🖥️, longer time to disease activity ⏳, but no significant impact on relapses ❌. Well-tolerated with minimal side effects ⚕️, These findings support further research on Vitamin D as an MS therapy 🔬🚀.
info_outline
BEAM-302: Rewriting Genes, Restoring Health – A Breakthrough in AATD Therapy! 🔬🚀
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🔬 BEAM-302 is a liver-targeting gene therapy using base editing to correct the PiZ mutation in Alpha-1 Antitrypsin Deficiency (AATD). 🧬 I t increases functional AAT 🫁 while reducing toxic Z-AAT, showing up to 78% reduction at the 60 mg dose. 📊 The Phase 1/2 trial demonstrated dose-dependent efficacy, a well-tolerated safety profile, and no serious adverse events (SAEs). 🛡️ With ongoing dose escalation and expansion to liver disease patients, BEAM-302 could be a one-time curative therapy 🚀, with further data expected in late 2025. 📅
info_outline
Dr. RR Baliga’s Philosophical Discourses: Confucius (China, 551–479 BCE) – Founder of Confucianism
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Confucius (c. 551–479 BCE), a renowned Chinese philosopher and teacher, founded Confucianism, emphasizing morality, family loyalty, social harmony, and virtuous governance. His teachings, compiled in the Analects, profoundly influenced Chinese culture, ethics, and education.
info_outline
“The Brain’s Switchboard 🔄: How MRN Controls Perseverance 🛑, Exploration 🚀 & Disengagement ❌”
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
This study identifies the Median Raphe Nucleus (MRN) 🧠 as a behavioral switchboard 🔄, regulating perseverance 🛑, exploration 🚀, and disengagement ❌ through distinct neuron types. GABAergic neurons 🟢 promote perseverance, Glutamatergic neurons 🔵 drive exploration, and Serotonergic neurons 🟠 maintain engagement. Using optogenetics 💡, fiber photometry 📈, and circuit tracing 🔗, researchers demonstrated how MRN integrates signals from the lateral hypothalamus (LHA) 🌟 and lateral habenula (LHb) ⚡ to control decision-making. These findings have clinical...
info_outline
“💊 High Intensity Statins vs Smart Alternatives: A Heart-Healthy Showdown! ❤️📉”
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🔬 Study Overview: A meta-analysis comparing alternative LDL cholesterol-lowering strategies (moderate-intensity statins + ezetimibe) vs high-intensity statins in patients with ASCVD. 📊 Key Findings: ✅ No significant difference in 3-year cardiovascular events (7.5% vs 7.7%) 📉 Lower LDL cholesterol in the alternative strategy (64.8 vs 68.5 mg/dL) 🩸 Reduced risk of new-onset diabetes (10.2% vs 11.9%) 💊 Fewer therapy discontinuations due to intolerance (4.0% vs 6.7%) ⚖️ Conclusion: The alternative strategy offers comparable efficacy with better tolerability and...
info_outline
“Stronger Bones, Fewer Fractures! 🦴🔍 USPSTF Osteoporosis Screening Guide”
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🦴 USPSTF Osteoporosis Screening Summary 📋 🔍 Why? Prevent fractures, disability, and mortality. 👩⚕️ Who? Women 65+ ✅, at-risk postmenopausal women ✅, men ❌ (insufficient evidence). 🩻 How? DXA scan (bone density test) is the gold standard. ⚠️ Risk Factors: Age, low weight, family history, smoking, alcohol, medications. ✅ Benefits: Reduces fracture risk with moderate evidence. ⚠️ Harms: Minimal risks, rare side effects from treatment. 📌 Takeaway: Screen women 65+ and younger high-risk women!
info_outline
“🫀 Cracking the Calcium Code: How CAC Scoring Transforms Cardiovascular Risk Assessment! 🔬📊”
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🫀 Cardiac CT Calcium Score: Key Insights 🔬📊 🔍 What is CAC? ✅ Measures calcified plaque in coronary arteries via cardiac CT 📸 ✅ Higher CAC = Higher cardiovascular risk ⚠️ ✅ Agatston Score: 0 (None) → >400 (Severe Atherosclerosis) 📊 Clinical Impact: ✅ Strong predictor of ASCVD events (MI, stroke, CHD death) 📉 ✅ MESA Study: CAC >300 → 10-year CHD risk: 13-25% ✅ CAC = 0 → Low risk, even for some statin-eligible patients 🚀 🎯 Guidelines & Utility: 📢 Used for risk stratification in intermediate-risk patients (7.5%-20%...
info_outline
Tirzepatide: Game Changer for Weight Maintenance 💊📉
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Tirzepatide & Weight Maintenance 💊📉 A phase 3 clinical trial (SURMOUNT-4) showed that continued use of tirzepatide helps maintain weight loss in adults with obesity. Participants on tirzepatide lost an extra 5.5%, while those on placebo regained 14%. ✅ 89.5% maintained at least 80% of their weight loss, compared to 16.6% on placebo. Common side effects were mild gastrointestinal issues 🤢. Stopping treatment led to significant weight regain, reinforcing the need for long-term therapy. 🔬
info_outlineCoronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland
Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*
Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.
Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.
Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).
Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.